| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000456869 |
| ISSN: | 0034-8376 |
| Autores: | Acun, Gokce1 Ozdemir, Hakan2 Sunamak, Oguzhan2 Unal Ozdemir, Zehra2 Baskan, Emel3 Yazi, Mete4 Savas, Berna5 Berberoglu, Ugur3 |
| Instituciones: | 1Beypazari Governmental Hospital, Department of General Surgery, Ankara. Turquía 2Haydarpasa Numune Training and Research Hospital, Department of General Surgery, Estambul. Turquía 3Ankara Oncology Training and Research Hospital, Department of General Surgery, Ankara. Turquía 4Kırıkkale Governmental Hospital, Department of General Surgery, Kırıkkale. Turquía 5Ankara University, Ankara Faculty of Medicine, Ankara. Turquía |
| Año: | 2018 |
| Volumen: | 70 |
| Número: | 6 |
| Paginación: | 279-284 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Intra-abdominal adhesions and their complications following abdominal surgery are serious problems, with an incidence of 67-93%. Prevention of peritoneal adhesion formation may eliminate the need for surgical intervention, decreasing complications, morbidity, and cost. Bevacizumab is a recombinant monoclonal antibody which specifically binds vascular endothelial growth factor, an important cytokine in adhesion formation, and neutralizes its biological activity. We developed an experimental model in rats to determine the effect of bevacizumab in preventing adhesion formation and analyzed its effect both micro- and macroscopically. Methods: We used 32 Wistar rats randomly divided into two groups: Group A (control) and Group B (bevacizumab), with 16 rats each. A modified cecum abrasion model was developed; 0.9% NaCl solution was administered intraperitoneally to Group A and bevacizumab to Group B. On day 15, adhesion formation was evaluated both macro- and microscopically. Results: Both micro- and macroscopic adhesion grades in Group B were significantly lower than those of control Group A; macroscopic grades were 2.69 ± 0.95 and 0.69 ± 0.8, and microscopic grades were 2.25 ± 1.06 and 0.5 ± 0.52 for Groups A and B, respectively. Conclusions: Bevacizumab was effective in preventing intraperitoneal adhesion formation in our study; however, its inhibitory effects on embryogenesis and the hematopoietic, endocrine, and immune systems may limit its clinical use. ( |
| Disciplinas: | Medicina |
| Palabras clave: | Cirugía, Gastroenterología, Farmacología, Cirugía abdominal, Adhesión peritoneal, Factor de crecimiento vascular endotelial, Bevacizumab |
| Keyword: | Surgery, Gastroenterology, Pharmacology, Abdominal surgery, Peritoneal adhesions, Vascular endothelial growth factor, Bevacizumab |
| Texto completo: | https://www.medigraphic.com/pdfs/revinvcli/nn-2018/nn186c.pdf |
